Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN20423 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | - |
| Part B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN20423 | DRUG | Administered per the protocol |
| Placebo | OTHER | Administered per the protocol |
Part A: Enrolls healthy participants Part B: Enrolls participants with atopic dermatitis Key Inclusion Criteria: Part A: 1. Is judged by the investigator to be in good health based on medical history, physical examination, vital signs, Electrocardiograms (ECGs), and laboratory safety testing at s...
REGN20423 is an investigational small molecule being developed by Regeneron Pharmaceuticals for dermatology. It is currently in Phase 1 clinical development, with a first-in-human trial assessing it in healthy adult participants and adults with atopic dermatitis.
REGN20423 is being studied for use in healthy volunteers and in adults with atopic dermatitis. The ongoing Phase 1 trial is evaluating the drug in both populations to assess its safety and tolerability.
REGN20423 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. The company is conducting a Phase 1 clinical trial of the drug.
REGN20423 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is currently being studied in a first-in-human trial that is recruiting participants.
REGN20423 is being studied in one Phase 1 clinical trial, NCT07527923, titled "First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis." The trial is recruiting in Belgium with an enrollment of 144 participants.
Yes, the Phase 1 trial of REGN20423, NCT07527923, is randomized, double-blind, and controlled. It is recruiting healthy volunteers and adults with atopic dermatitis, with a total planned enrollment of 144 participants.